02 April 2026
02 April 2026
The FDA has authorised the company to begin a US myomectomy trial through an investigational device exemption.
Actinogen anticipates final topline efficacy and safety results for the full 36-week treatment period in November 2026.
The collaboration will focus on advanced therapies, including weight loss.
Lumitrace is currently approved in China and the US, with submission to EU regulatory authorities pending.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
